follow us:Google+FacebookLinkedInTwitterVimeoRSS Feeds

advertisement

GSK enters hostile takeover of Human Genome Sciences

By - Last modified: May 9, 2012 at 10:48 AM

Back to Top Comments Print

GlaxoSmithKline, the British pharmaceutical company with a vaccine plant in Lancaster County, today said it will begin a bid to buy Maryland-based Human Genome Sciences Inc. by going directly to shareholders to buy the company's majority stock.

Human Genome Sciences, also known as HGS, wanted the companies to use a "strategic alternatives review process" before any possible deal, it said. Instead, GlaxoSmithKline today opted to offer HGS shareholders an 81 percent premium on their stock value with a per-share purchase price of $13. GlaxoSmithKline first announced its bid to buy HGS in April.

HGS developed technologies for two drugs GlaxoSmithKline is working on, including one entering clinical trials to treat heart disease and stroke, and another to control blood sugar levels and appetite.

HGS trades its shares on the Nasdaq under the ticker symbol HGSI.

GlaxoSmithKline, which has its vaccine filling and packaging plant in East Donegal Township, trades its shares on the New York Stock Exchange under the symbol GSK.

Jim T. Ryan

Jim T. Ryan

Jim T. Ryan covers Cumberland County, manufacturing, distribution, transportation and logistics. Have a tip or question for him? Email him at jimr@cpbj.com. Follow him on Twitter, @JimTRyanCPBJ.

advertisement
advertisement
  
  
advertisement
  
  
advertisement
Back to Top